On September 3, Gelunhui reported that Chengdu Easton Biopharmaceuticals (688513.SH) announced that in August 2024, the company did not implement share repurchases. As of the end of August 2024, the company had repurchased a total of 3,316,769 shares through centralized auction trading, accounting for 1.8788% of the company's current total share capital. The highest purchase price was 56.05 yuan/share and the lowest was 28.12 yuan/share, with a total transaction amount of RMB 123,694,177.73 (excluding stamp duty, transaction commission, and other trading expenses).
苑东生物(688513.SH)：8月公司未实施股份回购
Chengdu Easton Biopharmaceuticals (688513.SH): The company did not implement stock repurchases in August.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated